- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Palatin finalizes partnership with Mallinckrodt
The marketing alliance between biopharmaceutical start-up Palatin and healthcare giant Mallinckrodt for Palatin’s radiolabeled infection imaging agent, LeuTech (SCAN 5/26/99), has become official. Under the terms of the agreement,
The marketing alliance between biopharmaceutical start-up Palatin and healthcare giant Mallinckrodt for Palatins radiolabeled infection imaging agent, LeuTech (SCAN 5/26/99), has become official. Under the terms of the agreement, Mallinckrodt paid Palatin a licensing fee of $500,000 and acquired 700,000 restricted unregistered shares of Palatin preferred stock for an additional $13 million. An extra $10 million in milestone payments will be paid to Palatin upon Food and Drug Administration approval of the first indication for LeuTech, and the attainment of certain sales goals following the commercial introduction of this product. St. Louis-based Mallinckrodt will also reimburse Palatin for 50% of all ongoing LeuTech development costs, while Palatin, which is based in Princeton, NJ, will manufacture LeuTech and receive a transfer price on each product unit and a royalty on net LeuTech sales.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
